Novartis begins construction of two new radioligand therapy facilities in the US, expanding RLT manufacturing and supply network September 10, 2024
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 + KEYTRUDA in Patients with IO-Resistant HCC, Melanoma, and RCC September 3, 2024
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology September 3, 2024
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib September 3, 2024
CancerVax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment September 3, 2024
Foundation Medicine Collaborates with Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform September 3, 2024
Strategic Repositioning of VB10.16 to Focus on Locally Advanced Cervical Cancer and Recurrent Metastatic Head and Neck Cancer August 27, 2024
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m NSCLC August 27, 2024
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on ADC Drug Candidate Targeting Tissue Factor August 27, 2024
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement for Ph 1/2a Study of SON-1210 + Chemo for the Treatment of Pancreatic Cancer August 22, 2024
Pathos Expands Pipeline With Worldwide License of Ph 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor August 22, 2024
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical August 13, 2024
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers August 13, 2024
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines August 13, 2024
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai to Discover and Develop Novel Molecular Glue Degraders for Oncology Indications August 13, 2024
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 August 13, 2024
IDEAYA Biosciences Announces Option and License Agreement for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen August 7, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
Boehringer Ingelheim secures novel immune checkpoint inhibitors with acquisition of Nerio Therapeutics August 7, 2024
